Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 52-Week High – Still a Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)’s stock price hit a new 52-week high on Friday . The company traded as high as $30.00 and last traded at $29.8580, with a volume of 653989 shares trading hands. The stock had previously closed at $29.56.

Wall Street Analyst Weigh In

Several research firms have issued reports on CNTA. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an “outperform” rating and a $40.00 price objective for the company. Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Guggenheim boosted their price target on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Wells Fargo & Company upped their price objective on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, Chardan Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $35.50.

Centessa Pharmaceuticals Trading Up 1.2%

The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The stock has a market cap of $4.02 billion, a P/E ratio of -16.34 and a beta of 1.55. The business’s fifty day simple moving average is $25.09 and its 200 day simple moving average is $19.20.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 8,172 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total value of $174,880.80. Following the transaction, the insider directly owned 197,394 shares in the company, valued at approximately $4,224,231.60. This trade represents a 3.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total value of $1,040,000.00. Following the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. The trade was a 24.77% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 179,964 shares of company stock valued at $4,106,481. 7.09% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd boosted its stake in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after acquiring an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. acquired a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at $47,000. Fox Run Management L.L.C. acquired a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at $160,000. Vestal Point Capital LP bought a new position in shares of Centessa Pharmaceuticals in the 1st quarter worth $214,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth $218,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.